Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ROBERT A HOZMAN

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1659308237
CMS profile
119677
Location
SKOKIE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$16,764.60

421 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

Page 5 of 9; records 201–250 of 421 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ROBERT A HOZMAN

NPI 1659308237 · CMS profile ID 119677

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

SKOKIE, IL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 9; records 201–250 of 421 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1659308237?year=2023&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ROBERT A HOZMAN, NPI 1659308237, CMS profile ID 119677. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 9; records 201–250 of 421 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1659308237?year=2023&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). ROBERT A HOZMAN, NPI 1659308237, CMS profile ID 119677. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 9; records 201–250 of 421 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1659308237?year=2023&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
ROBERT A HOZMAN, NPI 1659308237, CMS profile ID 119677, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 9; records 201–250 of 421 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1659308237?year=2023&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

421 matching records · $16,764.60 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 421 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–250 of 421.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $8.2306/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997507635 CMS
ANI Pharmaceuticals, Inc. $19.9006/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034120387 CMS
ABBVIE INC. $1.1106/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997507631 CMS
ABBVIE INC. $1.9706/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997507633 CMS
GlaxoSmithKline, LLC. $14.6806/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003144931 CMS
Octapharma USA, Inc. $16.7806/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042725307 CMS
ABBVIE INC. $25.8906/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997507629 CMS
Fidia Pharma USA Inc. $18.9906/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1024736223 CMS
Amgen Inc. $10.3106/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020080583 CMS
PFIZER INC. $24.3506/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049245009 CMS
Novartis Pharmaceuticals Corporation $22.2506/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991989247 CMS
UCB, Inc. $24.1106/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021426291 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $21.8406/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997088649 CMS
GlaxoSmithKline, LLC. $23.3606/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003146409 CMS
E.R. Squibb & Sons, L.L.C. $19.4306/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015204237 CMS
E.R. Squibb & Sons, L.L.C. $0.9706/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015204245 CMS
Mallinckrodt Hospital Products Inc. $19.3806/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042841417 CMS
Mallinckrodt Hospital Products Inc. $0.8206/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042841413 CMS
UCB, Inc. $15.6606/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021426207 CMS
ABBVIE INC. $20.7706/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997507627 CMS
Amgen Inc. $14.5506/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020664249 CMS
Novo Nordisk Inc $18.2206/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1000423613 CMS
UCB, Inc. $14.6706/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021426197 CMS
ABBVIE INC. $2.5206/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997507621 CMS
ABBVIE INC. $13.1906/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997507623 CMS
ABBVIE INC. $1.9106/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997507625 CMS
Janssen Biotech, Inc. $4.1606/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988316313 CMS
Janssen Biotech, Inc. $19.6506/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988316293 CMS
AstraZeneca Pharmaceuticals LP $24.9406/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015767927 CMS
PFIZER INC. $26.4706/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049180339 CMS
ABBVIE INC. $23.7206/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997507619 CMS
Amgen Inc. $21.9906/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020080623 CMS
AstraZeneca Pharmaceuticals LP $17.8006/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014668677 CMS
E.R. Squibb & Sons, L.L.C. $153.7706/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015204229 CMS
ABBVIE INC. $29.9806/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997507617 CMS
Novartis Pharmaceuticals Corporation $16.1806/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991989239 CMS
Ironwood Pharmaceuticals, Inc $14.4206/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045569287 CMS
AstraZeneca Pharmaceuticals LP $21.4406/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016178621 CMS
Bio Products Laboratory USA, Inc. $14.2506/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022976609 CMS
E.R. Squibb & Sons, L.L.C. $30.0706/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015204221 CMS
PFIZER INC. $7.8606/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050577471 CMS
PFIZER INC. $4.1705/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049170255 CMS
Amgen Inc. $21.0805/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020664245 CMS
Amgen Inc. $21.0805/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020664247 CMS
Amgen Inc. $13.3305/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020080579 CMS
Mallinckrodt Hospital Products Inc. $28.4205/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042841405 CMS
Mallinckrodt Hospital Products Inc. $0.8205/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042841409 CMS
ABBVIE INC. $18.5005/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997507615 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $16.1005/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996618217 CMS
PFIZER INC. $22.1105/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050363301 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $34,062.94 493
PY2020 $32,480.37 419
PY2021 $16,013.85 491
PY2022 $15,044.58 434
PY2023 $16,764.60 421
PY2024 $18,702.20 440
PY2025 $18,725.36 424

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $413,374.35 63
PY2024 Principal investigator $328,896.36 85
PY2023 Principal investigator $369,966.04 80
PY2022 Principal investigator $426,739.18 141
PY2021 Principal investigator $470,828.07 117
PY2020 Principal investigator $609,642.45 95
PY2019 Principal investigator $409,370.05 74

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

63 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $7,070.00 12/22/2025 Non-covered Recipient Entity
CLINICAL INVESTIGATION SPECIALISTS
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175400162
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,675.73 12/17/2025 Non-covered Recipient Entity
CLINICAL INVESTIGATION SPECIAL
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223289888
Principal investigator 1 Janssen Research & Development, LLC $5,800.00 12/15/2025 Non-covered Recipient Entity
CLINICAL INVESTIGATION SPECIALISTS
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175400231
Principal investigator 1 ABBVIE INC. $3,604.60 12/04/2025 Non-covered Recipient Entity
CLIN INVESTIGATION SPECIALISTS INC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202528120
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,144.19 12/01/2025 Non-covered Recipient Entity
CLINICAL INVESTIGATION SPECIAL
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223289120
Principal investigator 1 Janssen Research & Development, LLC $8,070.00 11/27/2025 Non-covered Recipient Entity
CLINICAL INVESTIGATION SPECIALISTS
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175400258
Principal investigator 1 Novartis Pharmaceuticals Corporation $469.94 11/10/2025 Non-covered Recipient Entity
HOZMAN, ROBERT A, OFFICE
A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SL No dispute reported 06/30/2026 1190309310
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,017.25 11/07/2025 Non-covered Recipient Entity
CLINICAL INVESTIGATION SPECIAL
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223288155
Principal investigator 1 ABBVIE INC. $8,372.60 11/04/2025 Non-covered Recipient Entity
CLIN INVESTIGATION SPECIALISTS INC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202520091
Principal investigator 1 Janssen Research & Development, LLC $2,700.00 11/03/2025 Non-covered Recipient Entity
CLINICAL INVESTIGATION SPECIALISTS
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175400238
Principal investigator 1 Janssen Research & Development, LLC $10,705.00 10/27/2025 Non-covered Recipient Entity
CLINICAL INVESTIGATION SPECIALISTS
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175400220
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,675.73 10/15/2025 Non-covered Recipient Entity
CLINICAL INVESTIGATION SPECIAL
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223286997
Principal investigator 1 ABBVIE INC. $1,295.50 10/09/2025 Non-covered Recipient Entity
CLIN INVESTIGATION SPECIALISTS INC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202515867
Principal investigator 1 Janssen Research & Development, LLC $5,500.00 10/06/2025 Non-covered Recipient Entity
CLINICAL INVESTIGATION SPECIALISTS
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175400165
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $4,000.00 10/01/2025 Non-covered Recipient Entity
CLINICAL INVESTIGATION SPECIALISTS INC
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223286057
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $6,833.70 10/01/2025 Non-covered Recipient Entity
CLINICAL INVESTIGATION SPECIAL
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223286149
Principal investigator 1 Janssen Research & Development, LLC $12,405.00 09/29/2025 Non-covered Recipient Entity
CLINICAL INVESTIGATION SPECIALISTS INC
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175400264
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $29.07 09/24/2025 Non-covered Recipient Entity
CLINICAL INVESTIGATION SPECIALISTS INC
INSPIRE LTE study No dispute reported 06/30/2026 1246431040
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $926.96 09/04/2025 Non-covered Recipient Entity
Clinical Investigation Specialists, Inc
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (POETYK SLE-2) No dispute reported 06/30/2026 1235998062
Principal investigator 1 ABBVIE INC. $3,567.80 09/03/2025 Non-covered Recipient Entity
CLIN INVESTIGATION SPECIALISTS INC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202507395
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,544.75 09/03/2025 Non-covered Recipient Entity
CLINICAL INVESTIGATION SPECIALISTS INC
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223284917
Principal investigator 1 Janssen Research & Development, LLC $7,335.00 08/28/2025 Non-covered Recipient Entity
CLINICAL INVESTIGATION SPECIALISTS INC
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175400177
Principal investigator 1 Janssen Research & Development, LLC $3,650.00 08/28/2025 Non-covered Recipient Entity
CLINICAL INVESTIGATION SPECIALISTS INC
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175400182
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,000.00 08/22/2025 Non-covered Recipient Entity
CLINICAL INVESTIGATION SPECIALISTS INC
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223284537
Principal investigator 1 Eli Lilly and Company $3,500.00 08/20/2025 Non-covered Recipient Entity
CLINICAL INVESTIGATION SPECIALISTS INC
A RANDOMIZED, CONTROLLED PRAGMATIC PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187879165
Principal investigator 1 ABBVIE INC. $13,500.00 08/06/2025 Non-covered Recipient Entity
CLIN INVESTIGATION SPECIALISTS INC
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202502336
Principal investigator 1 ABBVIE INC. $2,327.50 08/05/2025 Non-covered Recipient Entity
CLIN INVESTIGATION SPECIALISTS INC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202501152
Principal investigator 1 ABBVIE INC. $2,141.90 08/05/2025 Non-covered Recipient Entity
CLIN INVESTIGATION SPECIALISTS INC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202501154
Principal investigator 1 Janssen Research & Development, LLC $14,500.00 08/04/2025 Non-covered Recipient Entity
CLINICAL INVESTIGATION SPECIALISTS INC
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis No dispute reported 06/30/2026 1175400188
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,544.75 08/01/2025 Non-covered Recipient Entity
CLINICAL INVESTIGATION SPECIALISTS INC
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223283423
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,370.00 08/01/2025 Non-covered Recipient Entity
CLINICAL INVESTIGATION SPECIALISTS INC
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223283525
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,500.00 08/01/2025 Non-covered Recipient Entity
CLINICAL INVESTIGATION SPECIALISTS INC
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223283527
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $937.00 08/01/2025 Non-covered Recipient Entity
CLINICAL INVESTIGATION SPECIALISTS INC
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223283529
Principal investigator 1 Janssen Research & Development, LLC $7,535.00 07/28/2025 Non-covered Recipient Entity
CLINICAL INVESTIGATION SPECIALISTS INC
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175400207
Principal investigator 1 ABBVIE INC. $8,500.00 07/25/2025 Non-covered Recipient Entity
CLINICAL INVESTIGATION SPECIALISTS
A Study to Evaluate Efficacy and Safety of Upadacitinib in Adult Participants With Axial Spondyloarthritis No dispute reported 06/30/2026 1202499768
Principal investigator 1 ABBVIE INC. $349.00 07/02/2025 Non-covered Recipient Entity
CLIN INVESTIGATION SPECIALISTS INC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202496137
Principal investigator 1 ABBVIE INC. $2,750.00 07/02/2025 Non-covered Recipient Entity
CLIN INVESTIGATION SPECIALISTS INC
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202496139
Principal investigator 1 Janssen Research & Development, LLC $4,485.00 06/30/2025 Non-covered Recipient Entity
CLINICAL INVESTIGATION SPECIALISTS INC
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175400194
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $10,500.00 06/11/2025 Non-covered Recipient Entity
Clinical Investigation Specialists, Inc
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Nave to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNF Inhibitor Treatment No dispute reported 06/30/2026 1235998060
Principal investigator 1 Janssen Research & Development, LLC $24,725.00 06/09/2025 Non-covered Recipient Entity
CLINICAL INVESTIGATION SPECIALISTS INC
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175400170
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,000.00 06/04/2025 Non-covered Recipient Entity
CLINICAL INVESTIGATION SPECIAL
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 No dispute reported 06/30/2026 1223280682
Principal investigator 1 UCB SA $54,209.00 06/04/2025 Non-covered Recipient Entity
CLINICAL INVESTIGATION SPECIALISTS, INC
A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. No dispute reported 06/30/2026 1246658608
Principal investigator 1 ABBVIE INC. $5,997.90 06/03/2025 Non-covered Recipient Entity
CLIN INVESTIGATION SPECIALISTS INC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202488911
Principal investigator 1 ABBVIE INC. $1,500.00 05/15/2025 Non-covered Recipient Entity
CLINICAL INVESTIGATION SPECIALISTS
A Study to Evaluate Efficacy and Safety of Upadacitinib in Adult Participants With Axial Spondyloarthritis No dispute reported 06/30/2026 1202484961
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $174.42 05/07/2025 Non-covered Recipient Entity
CLINICAL INVESTIGATION SPECIALISTS INC
INSPIRE LTE study No dispute reported 06/30/2026 1246431038
Principal investigator 1 ABBVIE INC. $3,943.00 05/06/2025 Non-covered Recipient Entity
CLIN INVESTIGATION SPECIALISTS INC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202481187
Principal investigator 1 Janssen Research & Development, LLC $16,605.00 05/01/2025 Non-covered Recipient Entity
CLINICAL INVESTIGATION SPECIALISTS INC
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175400271
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $1,650.87 04/23/2025 Non-covered Recipient Entity
CLINICAL INVESTIGATION SPECIALISTS INC
Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1) No dispute reported 06/30/2026 1246431032
Principal investigator 1 Vertex Pharmaceuticals Incorporated $8,841.15 04/09/2025 Non-covered Recipient Entity
CLINICAL INVESTIGATION SPECIALISTS INC
A Randomized, Double-blind, Placebo-controlled Study of ALPN-101 in Systemic Lupus Erythematosus No dispute reported 06/30/2026 1214124052
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,440.60 04/08/2025 Non-covered Recipient Entity
HOZMAN, ROBERT A, OFFICE
A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Phase 3 Study to Evaluate Efficacy, Safety and Tolerability of Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SL No dispute reported 06/30/2026 1190302301
Principal investigator 1 ABBVIE INC. $2,243.75 04/03/2025 Non-covered Recipient Entity
CLIN INVESTIGATION SPECIALISTS INC
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202471852
Principal investigator 1 ABBVIE INC. $5,443.00 04/03/2025 Non-covered Recipient Entity
CLIN INVESTIGATION SPECIALISTS INC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202471856
Principal investigator 1 ABBVIE INC. $9,127.50 03/07/2025 Non-covered Recipient Entity
CLIN INVESTIGATION SPECIALISTS INC
M23-699 - Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) No dispute reported 06/30/2026 1202460907
Principal investigator 1 ABBVIE INC. $3,239.30 03/06/2025 Non-covered Recipient Entity
CLIN INVESTIGATION SPECIALISTS INC
M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202457863
Principal investigator 1 SUN PHARMACEUTICAL INDUSTRIES INC. $967.14 03/03/2025 Non-covered Recipient Entity
CLINICAL INVESTIGATION SPECIALISTS INC
INSPIRE LTE study No dispute reported 06/30/2026 1246431028
Principal investigator 1 Janssen Research & Development, LLC $4,900.00 02/20/2025 Non-covered Recipient Entity
CLINICAL INVESTIGATION SPECIALISTS INC
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175400245
Principal investigator 1 UCB SA $1,279.00 02/18/2025 Non-covered Recipient Entity
CLINICAL INVESTIGATION SPECIALISTS, INC
A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. No dispute reported 06/30/2026 1246657692
Principal investigator 1 Janssen Research & Development, LLC $12,500.00 02/17/2025 Non-covered Recipient Entity
CLINICAL INVESTIGATION SPECIALISTS INC
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175400226
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 02/17/2025 Non-covered Recipient Entity
CLINICAL INVESTIGATION SPECIALISTS INC
?A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 3 Protocol to Assess the Efficacy and Safety of Nipocalimab in Adults with Moderate to Severe Sjgren's Disease (SjD)? No dispute reported 06/30/2026 1175400253
Principal investigator 1 ABBVIE INC. $3,234.20 02/05/2025 Non-covered Recipient Entity
CLIN INVESTIGATION SPECIALISTS INC
M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202445498
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $43,223.55 01/21/2025 Non-covered Recipient Entity
Robert Hozman Health
A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjgren's Syndrome (POETYK SjS-1) No dispute reported 06/30/2026 1235994191
Principal investigator 1 Novartis Pharmaceuticals Corporation $87.00 01/15/2025 Non-covered Recipient Entity
HOZMAN, ROBERT A, OFFICE
A Randomized, Double-blind, Placebo Controlled, 3-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren's Syndrome (NEPTUNUS-2) No dispute reported 06/30/2026 1190302299
Principal investigator 1 ABBVIE INC. $2,210.00 01/02/2025 Non-covered Recipient Entity
CLIN INVESTIGATION SPECIALISTS INC
M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) No dispute reported 06/30/2026 1202435509